Concepedia

Mitigation of acute radiation-induced brain injury in a mouse model using anlotinib

Xiaohan Gao, Jing Zheng, Long Ma, Longbo Ma, Yujie Zhai, Fangfang Yang, Shengjie Wang, Qing-Shuai Fan, Jie Wen, Henglu Wang,

Annals of Palliative Medicine · 2021 · 12 citations · 28 references

DOIFull text

Open access

Abstract

In summary, treatment with anlotinib significantly mitigated the adverse effects of acute RBI in a dose-dependent manner by downregulating the activation of astrocytes, improving brain hypoxia, and alleviating cerebral edema.

References

28

Purification and Characterization of Hypoxia-inducible Factor 1

Guang L. Wang, Gregg L. Semenza · Journal of Biological Chemistry · 1995 · 2.1K citations · Full text

Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System

Victor A. Levin, Luc Bidaut, Ping Hou et al. · International Journal of Radiation Oncology*Biology*Physics · 2010 · 708 citations

, , +9

Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?

Robert S. Kerbel · Science · 2006 · 470 citations

, , +13

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor

Chengying Xie, Xiaozhe Wan, Haitian Quan et al. · Cancer Science · 2018 · 363 citations · Full text

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Baohui Han, Kai Li, Yizhuo Zhao et al. · British Journal of Cancer · 2018 · 260 citations · Full text